Director Nan (ln) Li buys $20 million of Odyssey Therapeutics, Inc. (ODTX)
Nan (ln) Li, director, bought $20 million of stock. WallStPal Score 62.
Nan (ln) Li, director of Odyssey Therapeutics, Inc., bought 1,111,111 shares on the open market on May 11, 2026 at an average of $18.00 a share, for a total of $20 million. The purchase was reported to the SEC on Form 4 on May 11, 2026.
It raised their holding by 50%, to 3,333,516 shares.
6 other insiders also bought at least $10,000 of ODTX within 30 days, which makes this a cluster buy.
In the 12 months up to this filing, Odyssey Therapeutics, Inc. insiders reported 5 open-market purchases and 1 sale.
WallStPal Score: 62 out of 100, because of raised their holding by 50%; a large purchase; 6 other insiders also bought.
What happened next: after 1 month the stock was down 5.1%; after 3 months the stock was up 13.1%. Based on weekly prices from the week of the purchase.
Source: SEC Form 4 filing ↗. This story was written automatically from the filing and weekly price data. Information, not investment advice.
Examples
Big insider purchases have made news before. In January 2016, with bank stocks falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares, about $26 million of his own money, and the purchase was widely reported as a sign of confidence.
Explain it like I'm 13
Nan (ln) Li helps run Odyssey Therapeutics, Inc.. Spending $20 million of their own money on the company's stock is like a coach buying a big stack of tickets to their own team's games: it suggests they think the team will do well. It is not a promise, and insiders can be wrong.